FR3028410A1 - MULTIFUNCTIONAL CAPSULAR IMPLANT - Google Patents

Abstract

The present invention relates to a capsular implant (1), characterized in that it comprises a filiform body (6) having a plurality of contiguous segments, the filiform body (6) having a peripheral surface (5) which defines at least one arc an outer circle (x) along the filiform body (6) and at least one inner arc (y) along the filiform body (6), the filiform body (6) comprising at least one fastening means (2) an active formulation and / or an analysis or measurement device and / or a device for controlling the release of active principle (s), said fixing means (2) being arranged on the peripheral surface (5) of said filamentary body (6) along said inner circle arc (y) and allowing direct contact between said formulation and / or said device (s) and the capsular medium. It also relates to the use of said capsular implant (1) in the context of a post-operative management of a lens surgery in humans or animals.

Description

The present invention relates to the field of ophthalmology.  In particular, it relates to circular, open circular, semicircular or pseudo-circular capsular implants having a possibility of release of active principle (s) in the eye, and / or of incoporation of analysis devices or measurement.  Ophthalmic surgery and the administration of active ingredients in the eye pose a number of problems, due to the difficulty of access to the interior of the eye, the frequency of instillation of eye drops, and the meticulousness required by certain manipulations.  In addition, there are many problems raised by the release itself and its mechanical support which must respect both the current data of science and good surgical practices.  [0003] In the field of ophthalmic surgery, lens surgery has an important place.  It consists mainly of two types of surgery: - cataractous lens surgery; - clear lens surgery.  [0004] The first type of lens surgery is cataractous lens surgery.  Cataract is a disease that is characterized by the partial or total opacification of the lens, natural converging lens located inside the eye, and more specifically within an envelope called capsular bag.  This opacification is responsible for a gradual decline in vision, all the more important as opacification is important.  Cataract is by far the most common cause of blindness worldwide.  Indeed, more than 10% of the world's population over 65 is affected, as well as 60% of the world's population over 85 years of age.  The prevalence increases with age.  Cataract is found in nearly 40% of the 37 million blind people in the world, and according to WHO standards, there are 20 million blind individuals due to bilateral cataract.  It is therefore a major public health problem, and even if the treatment is known and reliable, its application is limited, in particular, by problems of cost, competence, accessibility and post-treatment options. procedure.  The main contributing factors are the following: undernutrition, dehydration, sun exposure, poor living conditions, genetic factors, etc.  When these risk factors are present, cataract can occur in a relatively young population, as is the case in some developing countries.  [0009] The global situation is of sufficient concern for cataract treatment programs for entire populations to be organized.  In particular, we can cite the initiative of Dr. Sanduk Ruit, a Nepalese surgeon, who has removed more than 1400 cataracts from an Indonesian program.  Similar programs exist for other needy states, such as India, Pakistan, Nepal.  These programs are mainly organized in countries where, in addition to the aforementioned factors, there are genetic factors that explain the number of cataracts.  Cataract surgery is then performed on a large scale by surgeons who sometimes perform up to 6000 to 7000 cataracts / year.  Under these conditions, it is difficult to have satisfactory postoperative management.  [00010] Usually, cataract therapy includes surgery as well as a demanding post-operative management, particularly involving the administration of eye drops and nursing care.  If cataract is mainly considered a human pathology, a number of animals also suffer.  The animal therapy also has certain additional constraints of cost and adaptability of the devices.  Indeed, most of the time, no health insurance is underwritten for the animals, and the entire treatment is the responsibility of the master / breeder.  In addition, more specifically concerning cataract therapy, post-operative cataract treatments are particularly difficult to administer to animals.  By way of example, this type of medicinal treatment may consist of the instillation of eye drops 3 times a day for 30 to 45 days, which can constitute a considerable loss of time for the master / breeder.  [00013] Finally, the diversity of animal morphologies is a constraint.  Each implant will indeed have a geometry adapted to the capsular bag of the animals concerned.  [00014] The second type of lens surgery is clear lens surgery.  It consists of the removal of a non-cataracted crystalline lens, the purpose of this removal being to improve certain vision disorders affecting the view of the patient concerned.  [00016] In practice, clear lens surgery is an effective and precise option for the correction of certain severe myopia, or certain hyperopia difficult or impossible to correct, or even some presbyopia.  At present, clear lens surgery is limited because of the benefit / risk ratio of such surgery.  This limitation is most often related to the age of the patient and the severity of his condition.  In practice, it is often performed in elderly patients with relatively severe eye problems.  [00018] Nevertheless, this surgery is brought to evolve, because of surer and safer surgical practices.  [00019] Therapy encompassing lens surgery (cataract or clear as appropriate), in the absence of complications, includes: lens surgery ("cataract / clear lens" surgery); during this procedure, the crystalline lens (cataract or clear as appropriate) is removed by destruction-aspiration and then replaced by an optical lens or optical implant, and - a demanding post-operative management; postoperative management consists of a postoperative polytherapy mainly based on antibiotics, steroidal anti-inflammatory drugs (steroids) and non-steroids, as well as nursing care dependent on autonomy and skill of the operated person.  [00020] According to the recommendations of the various colleges of ophthalmology, the post-operative management in humans may consist of: an antibiotic injected at the end of the procedure (for example cefuroxime); - eye drops (antibiotic one drop three to four times a day for ten days, steroids and nonsteroidal anti-inflammatory drugs one drop three times a day for at least one month); - many nursing care (3 times a day for about 1 month).  To this is added the management of the side effects of eye drops, a potential non-compliance of these treatments that can give infections with dramatic consequences.  For example, the eye drops may have the side effects of causing dry eye, conjunctival irritation, allergies.  [00023] These side effects are an unnecessary consultation reason found in the follow-up of almost 100% of patients who have undergone lens surgery.  For all these reasons, the post-operative care is today too expensive and very demanding compared to the price and ergonomics of the surgery itself.  Other blatant disadvantages are caused by the use of 10 eye drops.  In particular, it is very difficult to determine the amount of active ingredient administered, insofar as it depends on the quantity administered (difficulties related to the dosage, the quantity of the active ingredients administered is not controlled as it should be) and possible losses (passage of eye barriers, loss of product during administration).  [00026] In the medium term, after a lens surgery (cataract or clear), the patient very often develops a secondary cataract.  It corresponds to opacification of the capsular bag.  Indeed, some cells of the periphery of the bag migrate to the center of the visual axis.  This cell migration is responsible for a decrease in postoperative visual acuity by opacification of the posterior capsule and by diffraction of light.  This secondary opacification of the posterior capsule called capsulose is especially treated by YAG laser.  [00027] Finally, YAG laser therapy has a number of side effects: ocular inflammation, increased ocular tension, photophobia, increased risk of Iatrogenic retinal detachment, etc.  Very great progress has been made in the field of lens surgery in recent decades: a 12 mm incision, specialists have moved to incisions of only 2 mm or less.  Intraocular implants (lenses, capsular rings) must be capable of being inserted into such orifices.  They can be injected through an injector whose diameter is adapted to the size of the incision, or even arranged by the surgeon using various surgical instruments.  [00029] Despite the rapid evolution of the surgical technique, no major breakthrough has been observed in postoperative management.  [00030] Veterinary cataract surgery has also benefited from technological advances made in humans.  The lens is surrounded by a so-called "capsular bag", an ultra-thin membrane (elastic portion) that helps control its shape as the lens focuses on objects at different distances.  The capsular bag thus plays a fundamental role in accommodation processes under normal physiological conditions.  During a lens surgery, the capsular bag must be opened in a circular manner (capsulorhexis) so that the surgeon can access the lens.  It is crucial that its integrity be maintained, this in particular preventing the migration of fragments of the lens in the vitre and then on the retina.  [00034] The integrity of the capsular bag also makes it possible to position the optical implant correctly in its most physiological position possible.  If the capsular bag is broken during surgery, the postoperative management becomes even more cumbersome and more delicate.  [00035] In the longer term, the integrity of the capsular bag allows the positional stability of the optical implant and therefore of the refraction: even a minor migration of the optical implant forward or backward will be possible. cause significant visual disturbances and very disabling for the patient.  [00036] In summary, the capsular bag has a very important role in preserving the physio-mechanical balance of the eye (respect for the integrity of the blood-aqueous barrier).  This balance is, among other things, ensuring the proper positioning of the intraocular optical implant and its good stability over time.  [00037] Today, as part of the therapy including a crystalline lens surgery (cataract or clear depending on the case), it is necessary to have new solutions allowing simplified postoperative management and avoiding any risk. of infection (desired goal: zero infection).  In particular, there is a need for solutions allowing the provision of active ingredients, as well as other devices, directly in the capsular bag.  [00039] These solutions must not only allow simplified management (in particular by the elimination of eye drops and therefore nursing care), but also have other advantages, in particular the possibility of controlling the amount of active principle. the possibility of adding other active principles having other particular effects, as well as the possible integration of other devices, for example analysis and / or measurement devices and / or control of the release of active principle (s).  [00040] With regard to the administration of active principles, a number of solutions are known from the prior art.  Some devices are intended to allow the diffusion of active ingredients inside the eye, especially in the vitreous body.  Such implants are described in WO 02/43785, WO 02/02076, WO 04/026106 and WO 04/062649.  Other applications on behalf of ALLERGAN relatively close to those mentioned above can also be reported: WO 2005/105046, WO 2005/110362, WO 2005/107127, WO 2005/110436 or else WO 2008/070402.  Another application, on behalf of OCULEX, may also be reported: WO 95/13765.  [00043] These applications describe long-acting intraveneal implants whose OZURDEX® specialty is an illustration.  This specialty is particularly indicated in the treatment of adult patients presenting with macular edema following occlusion of the retinal venous branch or of the central retinal vein.  The granule thus implanted moves in the vitreous body, which can cause disturbances of the vision passengers simply due to its passage in the visual axis.  [00044] Other intra-vitreous implants are available on the market, such as the ILUVIEN® specialty, corresponding to the application WO 20 2011/079123 in the name of ALIMERA SCIENCE, INC.  Other devices for releasing active principles have been described in the following applications / patent: [00046] The application EP 0 322 319 in the name of OCULEX discloses implants intended to be inserted into the posterior or anterior chamber of the eye.  The application WO 2006/057859 in the name of THERAKINE discloses an ocular implant, unspecified regarding its implantation area.  The application WO 2010/093945 in the name of GLAUKOS CORPORATION discloses implants intended to be implanted in the uveoscleral zone.  EP 0 544 948 in the name of UNIVERSITY OF MIAMI discloses implants intended in particular to be implanted in the vitreous body.  [00047] Moreover, certain devices that can be recharged by invasive procedures have also been described.  This is particularly the case in the application WO 1993/03686 in the name of CUMMING, in which a relarguante capsule implanted intraocularly can / must be reloaded.  The release times of the capsule are not specified, probably because they are relatively short, hence the need to recharge it, which is problematic in terms of infection, ergonomic treatment, etc.  The application WO 2010/088548 in the name of FORSIGHT LABS INC.  discloses a rechargeable implant by a semi-invasive procedure, the implant 5 is inserted into the sclera.  The application WO 2009/140246 in the name of UNIVERSITY OF UTAH also has a device with a re-filling valve.  [00051] These rechargeable devices by invasive procedures are not satisfactory, just by the existence of such invasive procedures, having a number of drawbacks: reduced ergonomics of care, increased cost of care, possibility of creating a microbial entry door.  [00052] With regard to the diffusion and release modes, diffusion of active principles through hemipermeable membranes has been proposed, this being particularly the case in the aforementioned applications WO 2009/140246 in the name of UNIVERSITY OF UTAH and WO 2006/057859 in the name of THERAKINE.  In the case of the patent application WO 2009/140246, it is a hemipermeable film made of PES glued to the body of the implant to close a chamber in which the active ingredient has been introduced.  This room is not, therefore, open, but on the contrary, closed.  The hemipermeable membranes are obviously not a good solution: little adaptability to any pharmaceutical active principle, risk of rupture, design difficulties, variable contact area and difficult to control, etc.  Some teams have also worked on devices for the diffusion of active ingredients with multilayer systems and / or coatings.  [00055] In the application WO 03/061625 in the name of SNYDER & DOBRUSIN, an ophthalmic implant is presented including pharmaceutical molecules intended to be released outside the implant.  Whatever the embodiments, the active agent is located, at least in part, in a lower layer than another layer that is bioerodible.  This multilayer system 35 has a great disadvantage: multiplication of components of different nature, which can cause problematic erosions (separation of layers, etc.). ).  In addition, these devices are relatively difficult to formulate.  In the case of this application, any detachment of one or more releasing layers may be particularly dangerous, due to the sudden and massive release of pharmaceutical active principle into the eye (sudden increase in the surface area of the contact).  [00056] Other futile approaches of this type are presented in other applications.  In the application WO 2010/011585 in the name of ALCON, an ocular device releasing from a coating layer is described.  In the application WO 2012/106413 in the name of ABBOTT, a method of coating a lens by adhesion, impregnation etc.  is described.  In the application WO 2005/110364 in the name of ALLERGAN, a multilayer release device is also described.  In the application US 2012/213841 in the name of NOVARTIS, an intraocular biodegradable implant coated with a pharmaceutical active principle is described.  Finally, in the application WO 2004/016298 in the name of SCIMED LIFE SYSTEMS INC. multilayer systems are also described.  [00057] All of these solutions are extremely difficult to put into practice and / or are surgically unsuited to the current practices of lens surgery and / or are not very adaptable to several active principles, and / or require expensive developments, etc.  [00058] Probably due to the inapplicability of the multilayer / coating systems, some teams have worked on extremely complex release technologies.  An example of this type of technology is presented in US Patent 6,444,217 in the name of UNIVERSITY OF WASHINGTON: a system for releasing active agent from an implant is presented.  The active agent molecules are included in an entanglement of C10-C22 surface chains located on the surface of the implant.  A stimulus (sound or heat for example) allows the release of the active molecules by the organization / disorganization of chains C10-C22.  A similar system is described in WO 2008/113043 in the name of the same applicant.  These systems are particularly complex, and therefore difficult to adapt to different active ingredients.  [00061] Finally, certain approaches have been directed to complex structures presented as implantable in the eye.  [00062] To cite only one application, reference is made in WO 2013/096626 to ABBOTT MEDICAL OPTICS INC. , an ophthalmic implant in the form of "bone structure".  This frame can be in the form of cylindrical grid, springs etc.  (Figures 4 and 5).  This solution is unsatisfactory only from the implantability point of view, and the framework is obviously not implantable in the capsular bag under minimal incision conditions.  [00064] As regards the implants intended to be integrated in the capsular bag, two main types can be mentioned: intraocular lenses and capsular rings.  [00065] Intraocular lenses are devices intended to replace the lens (cataract or clear as the case may be), they are inserted into the capsular bag during the lens surgery.  They have optical properties allowing them to replace those of a normal lens.  In the prior art, some teams have focused their research on releasing lenses and having the appropriate optical properties.  This is particularly apparent from the application WO 2007/112946 in the name of UNIVERSITES DE GENEVA AND LAUSANNE as well as the application WO 97/06838 in the name of MASSACHUSETTS EYE & EAR INFIRMARY.  [00068] In general, given the mechanical constraints imposed on the lenses during their insertion through narrow orifices (especially in recent years because of the very large reduction in the size of the incision), it seems difficult. to load active ingredients.  Indeed, any "body" integrated in the thickness of the lens would be crushed or expelled.  Thus, the lenses can be adapted only by a simple coating (for example with heparin, or other pharmaceutical active principle) but can not under any circumstances release at the same time several active ingredients.  In addition, the lenses are processed for their optical properties and the preservation of these properties is often incompatible with the diffusion devices which imply a necessary erosion or evolution of the materials.  [00070] In order to prevent retraction of the capsular bag and contraction of capsulo-rhexis (capsulo-phimosis), capsular rings are widely used.  The capsular ring can be inserted during the lens surgery (cataract or clear) in the capsular bag.  It avoids the retraction of this last.  [00072] A number of terms are commonly used to designate a capsular ring: "capsular tension ring", "capsular equatorial ring", "tension ring", etc.  [00073] In the prior art, some teams have worked on capsular rings having particular properties, in particular for administering active principles.  [00074] Patent EP 1 696 832 in the name of MORCHER GmbH discloses a capsular ring having rigid segments made from acrylate as well as softer segments made from HEMA / PMMA hydrophilic flexible copolymers.  The ring shown in particular in the figures appears as immovable in minimal incision conditions, in that it is not open.  The invention is centered on the seemingly advantageous deployment of the capsular ring within the capsular bag.  It is specified that the flexible segments can be "judiciously impregnated" with a pharmaceutical active principle, but no other precision is given on the inclusion / diffusion mode.  [00075] Other approaches in which the mechanical considerations are preponderant exist.  In the application WO 2007/112946 in the name of INSIGHT INNOVATION is disclosed a mechanical barrier system for cell migration.  In WO 98/15238 in the name of CORNEAL, it is perceived as imperative to use non-biodegradable release systems because mechanical considerations are perceived as superior conditions.  This last request illustrates in particular the difficulties that exist in reconciling the release and satisfactory mechanical properties.  In the application WO 2001/35868 in the name of CORNEAL, a particular form of capsular ring is presented, this shape allows a better introduction into the injection system.  In the application WO 2004/069101 in the name of IOL-TECHNOLOGY-PRODUCTION, a mechanically acting anti-opacification capsular ring is described.  In the application WO 2011/151839 in the name of MIRLAY, an optical system having an improved alignment is presented.  [00076] The publication of B. Cochener (French Journal of Ophthalmology, Vol 30 26, No. 3 - March 2003, pp.  223-231) discloses a non-biodegradable capsular ring based on HPMA / MMA 75-25 releasing 5-FU for the prevention of secondary cataract).  The properties of the HPMA / MMA copolymer, and in particular its lipophilicity, allow the incorporation, within the material, of a particular pharmaceutical active ingredient, 5-FU, to fight against secondary cataracts.  The only compound included is 5-FU.  In the application WO 2014/058965 in the name of ALCON, it is presented an implant intended to be inserted into the eye, including a structure having haptics.  On the circular structure, an intraocular pressure sensor and an antenna are used in particular in the context of the glaucoma management.  The implant has a relatively complex structure, and must be inserted with a particular device, as shown in Figures 8, 9 and 10.  In addition to the cataract treatment, the capsular rings may have other uses, in particular the replacement of the capsular bag when the latter no longer exists: certain rings have been designed to mechanically support the optical implant, these rings can be sutured to the sclera.  These are rather special capsular rings.  In summary, as regards the prior art, it appears that the prior art discloses very few implants intended for the administration of active principles within the capsular bag.  [00080] There remains a need for a capsular implant having the following characteristics: 1) from a surgical point of view: the capsular implant is capable of being inserted after a minimum incision, corresponding to the current good surgical practices and future for example about 2 mm or less; 2) from a mechanical point of view: the capsular implant is likely to have mechanical characteristics conciliating a necessary rigidity and flexibility allowing insertion and easy positioning, whether by clamp or injector.  Moreover, the mechanical properties must evolve as little as possible over time, or even not evolve at all.  In addition, its mechanical properties must be adapted to the capsular environment and respect the integrity of the walls of the capsular bag and may further, in some cases, allow stabilization of the walls of the capsular bag; 3) from the point of view of pharmaceutical active principles administration: the capsular implant is capable of allowing the administration of one or more active principle (s), mainly in the capsular bag and / or in the chamber prior, these active principles, as well as their number, must be adaptable to a given patient, according to its physiological characteristics, 3028410 12 his (her) pathology (s).  The kinetics of delivery must be able to be regulated independently for each active principle; 4) from the point of view of manufacture: the capsular implant is likely to have a relatively simple design, so that it can be adapted to the widest variety of active ingredient, or even existing compositions on the market; 5) from the economic point of view: the capsular implant is likely to have a manufacturing cost compatible with its use in the mass operations of populations that do not have access to expensive treatments.  It must also be adaptable to animals, with minimal adaptations; 6) from the point of view of public health: the use of the capsular implant is likely to have the direct consequence of reducing the incidence of postoperative complications; 7) from the point of view of scalability: the capsular implant is likely to have an ability to adapt to new technologies (which may in particular derive from the miniaturization of existing technologies) that can be associated with it; 8) from the point of view of adaptability: the capsular implant is likely to be adaptable to a given patient.  Thus, the post-operative treatment may vary from one individual to another, depending on possible allergies to one or more active principle (s), or even needs of particular classes of additional active ingredients ( anticancer, etc. ), variable dosages, etc. in summary, the capsular implant must present a possibility of "therapeutic customization".  [00081] Surprisingly, a capsular implant having all the advantages mentioned could be achieved.  The object of the invention is a capsular implant, characterized in that it comprises a filiform body having a plurality of contiguous segments, the filiform body having a peripheral surface which defines at least one circular arc 3028410 13 outside along the filiform body and at least one inner circular arc along the filiform body, the filiform body comprising at least one means for fixing an active formulation and / or an analysis or measurement device and / or a device for controlling the release of active principle (s), said fixing means being disposed on the peripheral surface of said filiform body along said inner circle arc, and having a non-closed opening.  The object of the invention is a capsular implant, characterized in that it comprises a filamentary body comprising a plurality of contiguous segments, the filiform body having a peripheral surface which defines at least one outer circle arc on the outside. along the filiform body and at least one inner circular arc along the filiform body, the filiform body comprising at least one means for attaching an active formulation and / or an analysis or measuring device and / or a device for controlling the release of active principle (s), said fixing means being disposed on the peripheral surface of said filiform body along said inner circular arc and allowing a direct contact between said formulation and / or the one or more devices and the capsular medium.  [00084] The capsular implant which is the subject of the invention is adapted to the capsular environment and respects the integrity of the walls of the capsular bag.  It may also, in some cases, allow the stabilization of the walls of the capsular bag.  [00085] From the surgical point of view, the capsular implant according to the invention can be inserted with the most modern surgical methods providing for a minimum incision, of the order of 2 mm or even less (1.8 mm, 1 , 6 mm, etc. ).  In particular, it can be inserted with a commonly used injector, in which it can notably be unfolded and momentarily present a substantially rectilinear shape.  The capsular implant may also be inserted by the surgeon with forceps and / or any other ophthalmic surgical instrument.  Its surface does not have asperities or roughness / irregularities limiting its "sliding" (its implantation in the capsular bag - respect for fragility on capsular bag) in the ocular tissues.  [00086] Next, from the point of view of the delivery of active principles, it appears that the capsular implant object of the invention can be "loaded" into different active formulations easily prior to the packaging of the implant. (in a manufacturing plant, etc. and / or by the introduction of an active formulation by the surgeon directly before or even during the surgical procedure.  A polytherapy can thus be achieved by means of several active formulations.  The capsular implant that is the subject of the invention can also be adapted for use in animal ophthalmology, as well as in experimental ophthalmology.  [00087] From the manufacturing point of view, the capsular implant according to the invention has a limited number of components.  In particular, a single component can be used for the realization of the capsular implant, or only a limited number of components, to which will be added other components related to active formulations or other devices.  [00088] From the economic point of view, the simplicity of the capsular implant object of the invention has a real interest in its manufacture which is also easy to implement.  In addition, the post-operative treatment can be made much less expensive, and more easily achievable because the concepts of daily treatment and several times a day become obsolete.  In addition to the disappearance of compliance difficulties, the problem of the septic conservation of open eye drops is disappearing (hot countries, developing countries).  Thus the capsular implant becomes applicable to the greatest number.  [000891] Finally, from a mechanical point of view, the capsular implant object of the invention has no disadvantage compared to a conventional capsular ring.  Its diameter is not greater, its surface has no roughness or roughness / irregularity limiting its "sliding" in ocular tissues, its manipulation is not more delicate (does not question the codes of good collegially and academically accepted surgical practices), its ability to be disposed of in a possible setting device is retained.  The absence of roughness or roughness / irregularity allows compliance once in place of the walls of the capsular bag.  With respect to its strength, although material may have been removed from the implant, its mechanical strength is not impaired.  [00090] The active ingredients that can be used in the active formulations that can be attached to the capsular implant that are the subject of the invention are numerous, and are any active agent of interest.  The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the groups of antibiotics, anti-inflammatories, anti-glaucoma drugs, anti-cancer drugs, active ingredients used in the treatment of AMD, immunosuppressants, antivirals, antifungals, antiallergics, anesthetics and / or any other active agent that may be used to treat an eye pathology (retinopathies, uveitis, infections various of the eye) [00092] The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of antibiotics.  Some examples of usable antibiotics are given below: tetracyclines (daunomycin, tetracycline, chloretetracycline, oxytetracycline, etc.). ), glycopeptides (vancomycin, etc.) ), aminoglycosides (gentamycin, etc.) ), aminoglycosides (tobramycin, neomycin, etc.) ), fluoroquinolones (ciprofloxacin, moxifloxacin, etc.) ), quinolones (gatifloxacin, etc.) ), polypeptides (bacitracin, polymyxin, etc.) ), phenicolated (chloramphenicol, etc.) ), macrolides (erythromycin, etc.) ), sulfonamides (sulfacetamide, sulfamethoxazole, sulfisoxazole, etc.) ), and any other antibiotic.  The preferred antibiotics are those belonging to the quinolone and cephalosporin classes.  Regarding quinolones, they may be first-generation quinolones (nalidixic acid, oxolinic acid, pipemidic acid, piromidic acid, cinoxacin, flumequine, rosoxacin, etc.). ), second generation (balofloxacin, glepafloxacin, levofloxacin, pazufloxacin, sparfloxacin, temafloxacin, tosufloxacin, etc.) ), or even third generation (clinafloxacin, garenoxacin, gemifloxacin, moxifloxacin, gatifloxacin, sitafloxacin, trovafloxacin, prulifloxacin, etc.). ).  The active ingredients belonging to the particularly preferred quinolone family are ofloxacin and norfloxacin.  As regards cephalosporins, it may be a first-generation cephalosporin (cefacetrile, cefadroxil, cephalexin, cefaloglycin, cefalonium, cefaloridine, cefalotin, cefapirine, cefatrizine, cefazaflure, cefazedone, cefazolin, cefradine, cefroxadine, cefezole, cefaclor, etc.). ), second generation (cefamandole, cefuroxime, cefonicid, ceforanid, cefprozil, loracarbef, cefotetan, cefoxitin, etc.) ), third generation (cefotiam hexetil, ceftriaxone, cefotaxime, ceftizoxime, ceftazidime, cefoperazone, cefsulodine, ceftibuten, cefixime, cefatamet, cefpodoxime, etc. ) or even with extended spectrum (cefepime, cefpriome, etc.) ).  The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of anti-inflammatory, steroidal (AIS) and / or non-steroidal drugs (NSAIDs). ).  Some examples of AIS are given below: triamcinolone, dexamethasone, prednisolone, hydrocortisone, corticosterone, fluocinolone, prednisolone, methylprednisolone, fluorometholone, betamethasone, tetrahydrocortisol, rimexolone, etc.  Some examples of NSAIDs are given below: indomethacin, nepafenac, diclofenac, bromfenac, ketorolac, suprofen, etc.  [00094] Anti-inflammatories and antibiotics may especially be used as part of the post-operative management of crystalline surgery.  The active ingredients that can be used in the active formulations which can be attached to the capsular implant which is the subject of the invention may be chosen from the group of active principles used in the treatment of glaucoma, a certain number of active principles may be A nonlimiting list is given hereinafter: beta blockers (timolol, betaxolol, levobetaxolol, cardolol, atenolol, metipranolol, etc.). ), prostaglandin analogues (latanoprost, bimatroprost, travoprost, unoprostone, etc.) ), alpha-adrenergic receptor agonists (brimonidine, apraclonidine, etc.) ), ephinephrine and its derivatives, such as dipiverine hydrochloride, calcium antagonists (nimodipine, etc.). ), carbonic anhydrase inhibitors (acetazolamide, brinzolamide, dorzolamide, methazolamide, dichlorophenamide, etc.). ), myotic (pilocarpine, acetylcholine, isoflurophate, demecarium bromide, echothiophate iodide, phospholine iodide, carbachol, physostigmine, etc.) ).  The active ingredients which can be used in the active formulations which can be attached to the capsular implant which is the subject of the invention can be chosen from the group of anticancer agents, a nonlimiting list is given below: 5-fluoro uracil, methotrexate, adriamycin, tamoxifen, actinomycin, angiopeptin, avastine, mitotoxin, mitomycin, colchicine, daunomicin, etc.  [00097] Anti-cancer drugs may especially be used in the context of the prevention / treatment of secondary cataracts.  The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of active principles used in the treatment of AMD. A non-limiting list is given below: VEGF inhibitors (ranibizumab, pegaptanib or even aflibercept), anti-TGF-beta agents, integrin antagonist a5b1, rapamycin, PDGF inhibitors, integrin inhibitors, various anti-angiogenesis agents, etc.  The active ingredients that can be used in the active formulations that can be attached to the capsular implant which is the subject of the invention can be chosen from the group of immunosuppressants. A non-limiting list is given below: dexamethasone, betamethasone etc.  The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be selected from the group of antivirals, a nonlimiting list is given below: ganciclovir, trifluorothymidine, aciclovir, DDI, AZT, foscarnet, vidarabine, trifluorouridine, idoxuridine, ribavirin, protease inhibitors, anticytomegalovirus agent, etc.  [000101] The active ingredients that can be used in the active formulations that can be attached to the capsular implant which is the subject of the invention can be chosen from the group of antifungal agents. A nonlimiting list is given below: fluconazole, nitrofurazone , amphotericin B, ketoconazole, etc.  [000102] The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of antiallergics, a nonlimiting list is given below: methapyriline, chlorpheniramine , pyrilamine, prophenpyridamine, etc.  [000103] The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of anesthetics, a nonlimiting list is given below: lidocaine, mepivacaine etc.  [000104] The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of any other active ingredient that can be used to treat a pathology of the eye (retinopathies). , uveitis, various infections of: diabetic retinopathies (tolrestat, lisinopril, enelapril, etc.) ), DNA therapy or geno-therapy compounds, immunotherapy compounds, nanotherapy compounds, polypeptides, etc.  [000105] The other elements that can be integrated in the capsular implant which is the subject of the invention are numerous.  [000106] It may be: measurement and / or analysis devices intended to collect or transmit any type of ocular data; For example chips, biochips, antennas, microprocessors, various biological event sensors, detectors of markers or factors in the context of pathologies such as AMD, retinal melanoma or uvea, intraocular pressure, detector of presence of atypical cells, as well as other devices derived from nanotechnologies, etc.  control devices for the release of active ingredients.  [000107] The capsular implant according to the invention can be used in a large number of situations, a non-limiting list is given below: Postoperative management of crystalline surgeries (short term); In this use, the capsular implant has, in addition to the active principle (s) administration properties, a mechanical compatibility with the capsular environment, allowing in particular the maintenance of the integrity of the capsular bag.  It may also, in some cases, allow the stabilization of the walls of the capsular bag.  The integrated active principles are those conventionally used during post-operative management (eye drops / injections).  - Postoperative management of cataracts (medium / long term); It is possible to integrate active principles to avoid and / or delay secondary cataract or capsulose (such as 5-FU or methotrexate).  15 - Management of other pathologies; It is possible to integrate active principles whose indication is the treatment of inflammatory diseases of vitreous, inflammatory diseases of the retina, inflammatory disease of the anterior segment, macular edema (whatever their origin), age-related macular degeneration (AMD), chronic glaucoma, paroxysmal postoperative intraocular pressure surges in subjects at risk for cataract surgery or combined surgery: "corneal transplant + cataract" or "glaucoma + cataract, etc.

25 Integration of other devices; It is also possible to integrate certain devices, for example chips, biochips, antennas, microprocessors, various biological event sensors, marker or factor detectors in the context of pathologies such as AMD. retinal or uveal melanoma, intraocular pressure sensors, atypical cell detector, and other nanotechnology-derived devices, etc. [000108] All these uses can be cumulated. [000109] It is important to specify that the positioning of the capsular implant according to the invention does not generate additional risks that are not included in the known and accepted risks of cataract surgery. As a result, the possibility of treating other pathologies and / or complications without additional infectious risk is a real asset. In some cases, the capsular implant may be used to treat conditions that do not require lens surgery. In the latter case, a lens surgery will be performed for the sole purpose of inserting the capsular implant to treat these conditions.

In order to illustrate the invention, FIGS. 1 to 15B are hereinafter described. Figure 1: Sectional view of a semicircular capsular implant according to the invention Figure 1 shows a sectional view of a semicircular capsular implant 1 according to the invention comprising four chambers 2a in the filiform body 6 of implant 1. The chambers have openings 7 which are not closed. The outer circle arc x and the inner circle arc y, defined by the peripheral surface 5, are shown.

Figure 2: Sectional view of a semicircular capsular irrigator according to the invention Figure 2 shows a cross-sectional view of a semicircular capsular implant 1 according to the invention comprising two open chambers 2b in the 20 free ends of the implant 1. The chambers have openings 7 not closed, and the center distance taken in its smallest dimension z is shown. The outer circle arc x and the inner circle arc y, defined by the peripheral surface 5, are shown. The filiform body 6 is shown.

FIG. 3 is a sectional view of a semicircular capsular implant 1 according to the invention comprising four chambers 2a in the filiform body 6 of FIG. the implant 1 as well as two chambers 2b in the free ends 30 of the implant 1, and two transition zones 4. Said chambers 2a and 2b have openings 7 that are not closed, and the center distance taken in its smaller dimension z is shown for chambers 2b. The outer circle arc x and the inner circle arc y, defined by the peripheral surface 5, are shown.

FIG. 4 represents an external view of a semicircular capsular implant 1 according to the invention comprising two gripping zones 3. The peripheral surface 5 is an external view of a semicircular capsular implant 1 according to the invention. represented, just like the filiform body 6.

Figure 5: External view of a semicircular capsular implant according to the invention Figure 5 shows an external view of a semi-circular capsular implant 1 according to the invention comprising four open and non-closed chambers 2a in the filiform body 6 of the implant 1, two chambers 2b open in the free ends of the implant 1 and two gripping zones 3. The outer circular arc x and the inner circular arc y, defined by the peripheral surface 5, are shown.

Figure 5A shows a detail view of one of the two free ends of the implant 1. An open chamber 2b is present in the free end of the implant 1 shown. Figure 5B shows a detail view of an opening 7 of an open and non-closed chamber 2a in the filiform body 6 of the implant 1. One of the two gripping means 3 is shown. Figure 6: Sectional view of a semicircular capsular implant according to the invention in an injector cannula Figure 6 shows a sectional view of a semicircular capsular implant 1 according to the invention comprising four chambers 2a open and non-closed in the filiform body 6 of the implant 1, two open and non-closed chambers 2b in the free ends of the implant 1, the capsular implant 1 being inserted into an injector cannula.

Figure 7: Sectional view of a semicircular capsular implant according to the invention Figure 7 shows a sectional view of a semicircular capsular implant 1 according to the invention comprising two open and non-closed chambers 2a in the filiform body 6 of the implant 1 as well as two open and non-closed chambers 2b in the free ends of the implant 1. The openings 7 of the chambers 2a and 2b are shown. The outer arc x and the inner arc are represented. Figure 8: External view of a semicircular capsular implant according to the invention Figure 8 shows an external view of a semicircular capsular implant 1 according to the invention comprising four salient rings 2d, two open chambers 2b and not -closed in the free ends of the implant 1 and 3028410 21 two gripping areas 3. The filiform body 6 of the implant 1 is shown. The outer circle arc x and the inner circle arc y, defined by the peripheral surface 5, are shown. Figure 8A shows a detail view of one of the two free ends of the implant 1. An open chamber 2b is present in the free end of the implant 1 shown. Figure 8B shows a detail view of a projecting ring 2. One of the two gripping means 3 is shown.

Figure 9: External view of a semicircular capsular irrigant according to the invention Figure 9 shows an external view of a semicircular capsular implant 1 according to the invention comprising four open and non-closed surface chambers 2c filamentary body 6 of the implant 1, two open and non-closed chambers 2b in the free ends of the implant 1 and two gripping zones 3. The outer circular arc x and the inner circular arc y, defined by the peripheral surface 5, are represented. Figure 9A shows a detail view of one of the two free ends of the implant 1. An open chamber 2b is present in the free end of the implant 1 shown. Figure 9B shows a detail view of an open and non-closed surface chamber 2c of the filamentary body 6 of the implant 1. One of the two gripping means 3 is shown. Figure 9C shows a detail view of an open and non-closed surface chamber 2c of filamentary body 6 of implant 1. Figure 10: External view of a semicircular capsular itnplant according to the invention FIG. 10 represents an external view of a semicircular capsular implant 1 according to the invention comprising four projecting housings 2f in the filiform body 6 of the implant 1, two open and non-closed chambers 2b in the free ends of the implant implant 1 as well as two gripping zones 3. The outer circular arc x and the inner circular arc y, defined by the peripheral surface 5, are shown. Figure 10A shows a detail view of one of the two free ends of the implant 1. An open chamber 2b is present in the free end of the implant 1 shown.

Figure 10B shows a detail view of a protruding housing 2f in the filiform body 6 of the implant 1. Figure 11: External view of a semicircular capsular implant according to the invention Figure 11 shows a external view of a semicircular capsular implant 1 according to the invention comprising four coronellations 2e on the filiform body 6 of the implant 1, two open and non-closed chambers 2b in the free ends of the implant 1 as well as two gripping zones 3. The outer circle arc x and the inner circle arc y, defined by the peripheral surface 5, are shown. Figure 11A shows a detail view of one of the two free ends of the implant 1. An open chamber 2b is present in the free end of the implant 1 shown.

Figure 11B shows a detail view of a second cantilever on the filiform body 6 of the implant 1. The cantilever is made according to a first variant. Figure 11C shows a detail view of a 2nd cantilever on the filifome body 6 of the implant 1. The cantilever is made according to a second variant.

Figure 12: External view of a semicircular capsular implant according to the invention Figure 12 shows an external view of a semicircular capsular implant 1 according to the invention comprising a plurality of open and non-closed chambers 2a in the filamentary body 6 of the implant 1, and separated by partitions 9. The chambers 2a extend over almost the entire length of the implant 1. The chambers 2a have openings 7 unclosed. Figure 12A shows a sectional view along the axis AA '. There is shown a chamber 2a and its opening 7. The inter-axis taken in its smallest dimension z is shown. Figure 12B shows a schematic detail view of the peripheral surface of an end of the ring, showing a chamber 2a. Figure 13: External view of a semicircular capsular implant according to the invention Figure 13 shows an external view of a semicircular capsular implant 1 according to the invention comprising a plurality of open and non-closed chambers 2a in the body filamentary 6 of the implant 1. The open chambers 2a and 3028410 23 unclosed extend over almost the entire length of the implant 1, and are separated by partitions 9. The chambers 2a have openings 7 unclosed . Unlike Figure 12, the section of filiform body 6 is not round but rectangular.

Figure 13A shows a sectional view along the axis AA '. It shows a chamber 2a, and its opening 7. The inter-axis taken in its smallest dimension z is shown. Figure 13B is a schematic detail view of the peripheral surface of an end of the ring, showing a chamber 2a.

Figure 14: External view of a semicircular capsular implant according to the invention Figure 14 shows an external view of a semicircular capsular implant 1 according to the invention comprising four projections 2f in the filiform body 6 of FIG. the implant 1 as well as two open and non-closed chambers 2b in the free ends of the implant 1. The outer circular arc x and the inner circular arc y, defined by the peripheral surface 5, are represented. Unlike Figure 10, the section of filiform body 6 is not round but rectangular.

Figure 14A shows a detail view of one of the two free ends of the implant 1. An open chamber 2b is present in the free end of the implant 1 shown. Figure 14B shows a detail view of a projecting housing 2f in the filiform body 6 of the implant 1.

Figure 15: External view of a semicircular capsular implant according to the invention Figure 15 shows an external view of a semicircular capsular implant 1 according to the invention comprising a plurality of open and non-closed chambers 2a in the filamentary body 6 of the implant 1. The open and non-closed chambers 2a extend over a part of the length of the implant 1, and are separated by partitions 9. The chambers 2a have openings 7 that are not closed. . Figure 15A shows a sectional view along the axis AA '. There is shown a chamber 2a, as well as its opening 7. The inter-axis taken in its smallest dimension z is shown. The armature 8 of the capsular implant 1 is also shown.

Figure 15B shows a schematic side view of the peripheral surface of one end of the ring. [000111] The term "capsular implant" means an implant intended to be inserted into the capsular bag, which can adopt any shape, the only limit regarding the form is that the capsular implant must not interfere with the view. The term "fixing means" means any means for mechanically fixing: - an active formulation, said active formulation being gradually released into the capsular bag; then in all intraocular spaces by diffusion. AND / OR - measurement and / or analysis devices for collecting or transmitting any type of ocular data; For example chips, biochips, antennas, microprocessors, various biological event sensors, detectors of markers or factors in the context of pathology such as AMD, retinal melanoma or uvea, intraocular pressure, presence of atypical cells, other 20 devices from nanotechnologies, etc. It may be for example sensors as described in the application WO 2014/058965 in the name of ALCON previously mentioned. AND / OR - devices for controlling the release of active principles; For example a valve. It may in particular be a chamber created by recess or by molding the capsular implant, or even a projection created by adding material or molding. The fixing means, whether a chamber or projection, fixes the active formulation or the other integrable element by a mechanical action and / or any other means: glues, etc. The term "active formulation" any formulation comprising at least one active ingredient, being in solid form, pasty, gel or even liquid. [000115] "Analysis or measurement device and / or a device for controlling the release of active principle (s)" means any device whose placement in the capsular bag is of any interest. and whose size allows placement in / on the capsular implant object of the invention. The term "impregnation" means the method consisting of penetrating into the material (s) of the capsular implant one or more active principle (s). [000117] The term "open capsular implant" any capsular implant 5 non-continuous and having two free ends. [000118] The term "filiform body of the capsular implant" means the areas of the capsular implant not being the two free ends. The two free ends are present only when the implant is open (and therefore open circular or semicircular or open pseudo-circular). The filiform body has a peripheral surface which defines at least one outer circular arc and an inner circular arc along the filiform body. The fastening means are disposed on the peripheral surface of the filiform body along the inner arc and are open. The term "peripheral surface of the filamentary body" the surface 15 of the filamentary body of the implant being in contact with the outside. It forms a set of arcs of circle (variable angle according to the shape of the implant) of different diameters. The circular arc with the largest diameter is called the "outer circle arc", and the arc with the smaller diameter is called the "inner circle arc". When the implant is implanted in the capsular bag, the inner arc is that which is generally farthest from the walls of the capsular bag. [000120] The term "circular capsular implant" means a capsular implant having a circular shape, having an arc of 360 °. [000121] The term "semicircular capsular implant" means a capsular implant 25 having a semicircular shape. In one embodiment, the semicircular capsular implant has an arc of between 45 and 360 °. In one embodiment, the semicircular capsular implant has an arc of about 160 °, 180 °, 200 °, 220 °, 240 °, 260 °, 280 °, 300 °, 320 °, 340 °, 359 ° etc. In one embodiment, the semicircular capsular implant has an arc of about 240 °. In one embodiment, the semicircular capsular implant has an arc of about 340 °. The term "capsular pseudo-circular implant" means a capsular implant having a pseudo-circular shape, that is to say ovoid, or even polygonal with a number of side greater than a certain number, for example greater than 5 (hexagonal, heptagonal, octagonal, etc.). The implant may also have an asymmetrical shape with different radii of curvature, as for example in the application WO 01/35868 in the name of CORNEAL. The term "section of the capsular implant / filiform body of the capsular implant" means the shape of the section of the implant in an area in which the implant is full. The section may be of any compatible geometric shape: round, trigonal, tetragonal (square, rectangular), pentagonal, hexagonal, heptagonal, octagonal, or any other shape having a number of faces greater than 8. The shape of the section of the The implant can be chosen according to its ability to stop / limit the migration of the cells (this migration may cause a secondary cataract), it can for example be a square / rectangular shape commonly reported in the range of 10 lm. Ophthalmology by the term "square edges", ie square section. [000124] "Open and non-closed chamber" means all fastening means being in the form of an area of volume, shape and variable geometry, in which the material constituting the implant is emptied, or molded to the desired shape to leave room for various elements: active formulations in solid form or any other analysis or measurement device and / or a control device for the release of principle (s) active (s). We can distinguish several types of chamber: the open and non-closed chambers of the threadlike body of the implant, the open and non-closed chambers in the filiform body of the implant (the first being shallower than the 20 seconds ), the open and unclosed chambers in the free end of the implant (when the latter is open). In one embodiment, the implant has a plurality of open and non-closed chambers in the filamentary body of the implant, these chambers extending over almost the entire length of the implant. In the latter case, these rooms are separated by partitions or zones without rooms. The term "partition" means an isolation means relative to each other of the various open and unclosed chambers in the filiform body of the implant, when the latter are separated only by said partition. The material constituting the septum may be the same as or different from that of the capsular implant. The partition is exclusively found in the embodiments in which the capsular implant comprises a succession of open and unclosed chambers of the same shape in the filiform body of the implant. For example, the partition may have a thickness of 0.2 to 2 mm, or more or less. By "non-closed opening of the chamber" is meant the communication zone between the chamber and the outside of the chamber. This is an area of variable geometry, having an area (light) compatible with the release of active ingredient, as well as with the establishment and maintenance of the various elements that can be incorporated in the chamber (active formulation, device 3028410 27 analysis or measuring device, control device for the release of active principle (s), etc.) This unclosed opening is not closed by the installation or addition of additional material, such as whether a porous or non-porous film, perforated or not, or a membrane as described in the prior art, it is therefore defined as an integral part of the chamber. The term "protrusion" means any fastening means not being constituted by a recess or a recessed shape, but constituting one or more outcrops on the filiform body of the capsular implant. The protrusion can adopt any form allowing a mechanical attachment or of another nature (glues, etc.). It may for example be rings protruding from the filiform body of the implant, housing protruding on the filiform body of the implant, corbels on the filiform body of the implant, etc. These fixing means are never used on the free ends of the implants. [000128] The term "gripping zone" means an area allowing the capsular implant to be grasped and accurately moved by an ophthalmic forceps or any other instrument used in ophthalmic surgery, this gripping zone may be used to finish positioning the capsular implant in the bag, but may also, when the capsular implant has an open circular or semicircular or pseudo-circular structure, serve to rotate the capsular implant in the capsular bag to dispose of it adequately. The gripping zone consists of thinning and / or thickening, the geometric shape of which will assist in gripping by any type of surgical instrument used in the eye. The gripping zone may also be an absence of material (we will then call this zone a "digging zone"), whatever its geometrical shape, which could be used to mobilize the capsular implant by a hook or the like. instrument or cannula without this being a real prehension. Any type of gripping area and / or mobilization of the capsular implant so as to position and / or mobilize and / or rotate may adopt any type of geometric shape on the capsular implant as far as they are concerned. respect the integrity of the capsular bag during the insertion of this same capsular implant in the capsular bag. For example, in the case where the capsular implant has an open circular or semi-circular or pseudo-circular shape, the grip area may help position the recesses upwardly to oppose gravity. [000129] The term "transition zone of the capsular implant" means a zone having different mechanical properties that can be used to optimize the flexion, flexibility, elasticity of the capsular implant to facilitate its insertion into the capsular bag. These different mechanical properties are obtained either by an absence of material or by a different material. Areas that have been recessed as previously defined are explicitly excluded from the definition of "transition zones". These transition zones can be absent, unique or multiple. [000130] "Release of active principle" is understood to mean any transfer of active principle from the active formulation contained in the capsular implant to the external medium, in the specific case in the capsular bag and by diffusion from the latter. The term "wall of the capsular bag" the wall of the envelope 10 surrounding the lens, it is an ultra-thin envelope. The term "reinforcement of the capsular implant" means a reinforcement made of a material having a greater rigidity than that of at least one material of said capsular implant. The framework of the capsular implant has a section that can be of any geometric shape: round, trigonal, tetragonal 15 (square, rectangular), pentagonal, hexagonal, heptagonal, octagonal, or any other shape having a number of faces greater than 8 In one embodiment, this reinforcement is made of at least PMMA (poly (methyl methacrylate)). The armature may extend the entire length of the capsular implant, or only a portion of the length of the capsular ring.

The armature may be present regardless of the shape of the section of the capsular implant.  The term "direct contact" means a contact without medium or intermediate body between the formulations and / or devices and the middle of the capsular bag; for example without the presence of film and / or membrane.  When the fixing means is a chamber, it has a so-called open opening.  The capsular implant object of the invention may be made of any biologically compatible material.  The capsular implant which is the subject of the invention may consist of a material composed of at least one polymer.  In one embodiment, the polymer is chosen from acrylic polymers chosen from the group comprising PMMA (poly (methyl methacrylate)), HPMA (hydroxypropyl methacrylate), MMA (methyl methacrylate), BMA ( butyl methacrylate), HMA (hexyl methacrylate), LMA (lauryl methacrylate), HEMA (polyhydroxyethylmethacrylate), PEMA (poly (ethyl methacrylate)) and / or copolymers of these polymers and / or mixtures thereof, the polymers being be crosslinked or uncrosslinked.  29 is selected from the group consisting of: [000137] In one embodiment, the hydrophilic acrylic polymer polymer.  In one embodiment, the hydrophobic acrylic polymer polymer.  In one embodiment, the polymer is chosen from vinyl polymers chosen from the group comprising copolymers of polyvinyl alcohol (PVA), vinyl acetate-ethylene (EVA) and / or copolymers of these polymers. polymers and / or mixtures thereof, the polymers being cross-linked or non-cross-linked.  In one embodiment, the polymer is chosen from silicone polymers, siloxanes and / or copolymers of these polymers and / or their mixtures, the polymers being able to be crosslinked or non-crosslinked.  [000141] In one embodiment, the polymer is selected from the other polymers selected from the group consisting of polysulfone hair fibers, PEEK (polyether ether ketone), PAEK (polyaryl ether ketone), polyetherimide, polyimide, polyesters, polypropylene, polycarbonates, nylons and / or copolymers of these polymers and / or mixtures thereof, the polymers being cross-linked or non-cross-linked.  These polymers will be hereinafter called "other polymers".  In one embodiment, the polymer is chosen from acrylic polymers, vinyl polymers, silicone polymers, siloxanes, the other polymers and / or copolymers of these polymers and / or their mixtures, the polymers being able to be crosslinked or uncrosslinked.  [000143] In one embodiment, the capsular implant according to the invention consists of assembly of structures, each structure having different types of polymers and / or polymers of different molecular mass and / or polymers having different levels. different crosslinking.  [000144] In one embodiment, the capsular implant is constituted by assembling structures, one of whose structures is made of silicone polymer, said structure made of silicone polymer being, at least in part, in contact with the walls of the capsular bag.  [000145] In one embodiment, the capsular implant is constituted by assembling structures, one of whose structures is made of silicone polymer, said structure made of silicone polymer being the only one in contact with the walls of the capsular bag.  [000146] In fact, silicone polymers are particularly useful for combating secondary cataracts, and they are in this respect recognized by the FDA.  [000147] In one embodiment, the capsular implant is constituted by a structure assembly, at least one of which constitutes a reinforcement or core of the capsular implant.  In one embodiment, the armature or core consists of at least one rigid polymer such as PMMA (poly (methyl methacrylate)).  [000149] In one embodiment, the capsular implant is formed of several portions of variable compositions, such as, for example, rigid PMMA segments and more flexible HEMA-MMA copolymer segments, this is especially described in the EP patent. 1,696,832 to MORCHER GMBH.  [000150] In one embodiment, in order to limit cell adhesion and therefore inflammatory reactions, the capsular implant which is the subject of the invention is treated (by impregnation, grafting and / or any other surface treatment) with certain other compounds, such as, for example, fluorinated derivatives or even polysaccharides: heparin and derivatives, hyaluronic acid, sulphated polysaccharides, etc.  [000151] In one embodiment, the capsular implant that is the subject of the invention is treated with fluorinated derivatives.  In one embodiment, the capsular implant that is the subject of the invention is treated with heparin or its derivatives.  In one embodiment, the capsular implant according to the invention is treated with hyaluronic acid.  In one embodiment, the capsular implant that is the subject of the invention is treated with a sulphated polysaccharide.  [000155] The capsular implant object of the invention may further be treated (by impregnation, grafting and / or any other surface treatment) with one or more active principle (s).  It can be active principles mentioned above, or other active ingredients.  The active formulations that can be integrated in / on the capsular implant which is the subject of the invention are very numerous.  [000157] The formulations may be biodegradable or non-biodegradable.  In one embodiment, the active formulations comprise, in addition to the active ingredient, at least one polymer selected from the group of polylactic / polyglycolic polymers comprising PLA (polylactic acid), PLLA (L-polylactic acid), PGA (polyglycolic acid), PLGA (polylactic-co-glycolic acid), PGLC (poly (glycolide-co-lactide-co-caprolactone)) and / or copolymers of these polymers and / or mixtures thereof, polymers May be crosslinked or uncrosslinked.  In one embodiment, the active formulations comprise, in addition to the active ingredient, at least one polymer selected from the group of vinyl polymers including PVA (polyvinyl alcohol), EVA (vinyl ethylene acetate), polyvinylpyrrolidones and and / or copolymers of these polymers and / or mixtures thereof, the polymers being cross-linked or non-cross-linked.  In one embodiment, the active formulations comprise, in addition to the active ingredient, at least one polymer chosen from the group of polysaccharides comprising hyaluronic acid, chitosan, chondroitin, maltodextrin, amylose, keratane, dextran, heparin, polyalditol, pentosan, starch and / or copolymers of these polymers and / or mixtures thereof, the polymers being cross-linked or non-cross-linked.  In one embodiment, the active formulations comprise, in addition to the active ingredient, at least one polymer selected from the group of other formulation polymers including PEG (polyethylene glycol), PCL (polycaprolactone), polyanhydrides, silicone carbide, polysulfone, POE (polyorthoesters), polyanhydrides, polyamines, polyurethanes, polyesteramides, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, poly (malic acid), the poly (amino acids), the poly-tyrosine polymers, the poloxamer and / or the copolymers of these polymers and / or their mixtures, the polymers being able to be crosslinked or non-crosslinked.  These polymers will be hereinafter called "other formulation polymers".  In one embodiment, the polymers are selected from the group consisting of polylactic / polyglycolic polymers, vinyl polymers, polysaccharides, other formulation polymers and / or copolymers of these polymers and / or mixtures thereof, the polymers may be crosslinked or uncrosslinked.  The active formulations may be in any form having various rheological properties, thus having particular in solid forms, liquid, pasty, gels, etc.. , adapted to the fastening means.  [000164] In one embodiment, the capsular implant according to the invention is characterized in that at least one active formulation having a variable viscosity, ductility and rigidity.  [000165] They can be biodegradable or non-biodegradable.  The active formulations that can be incorporated into the capsular implant that is the subject of the invention must be chosen according to: the desired treatment (choice of active principle (s)); - the duration of the desired treatment; - the period chosen for such treatment (beginning of the immediate or deferred release).  For example, a capsular implant according to the invention may comprise the following formulations: - active formulation 1: a formulated antiobiotic, for example cefuroxime, the formulation allowing a release for about 7 days, and starting immediately after implantation; active formulation 2: a formulated anti-inflammatory, for example triamcinolone, the formulation allowing a release for about 30 days, and starting immediately after implantation; active formulation 3: a formulated anti-cancer, for example 5-FU, the formulation allowing a programmed release, and starting 2 to 3 months after implantation; - other device: an eye pressure sensor.  [000168] This example of a capsular implant will allow antibiotic / anti-inflammatory treatment useful in the context of management after lens surgery.  The release, in the medium term, of anticancer will prevent and / or treat a possible secondary cataract.  Finally, the regular measurement of the eye pressure, as well as its transmission without any invasive step, will facilitate the management, in parallel, of glaucoma.  [000169] The invention relates to a capsular implant 1 characterized in that it comprises a filiform body 6 having a plurality of contiguous segments, the filiform body 6 having a peripheral surface 5 which defines at least one outer circular arc x the along the filiform body 6 and at least one inner circular arc 30 along the filiform body 6, the filiform body 6 comprising at least one attachment means 2 of an active formulation and / or an analysis device or measuring and / or a device for controlling the release of active principle (s), said fixing means 2 being disposed on the peripheral surface 5 of said filiform body 6 along said inner circle arc and having a non-closed opening.  [000170] The invention relates to a capsular implant 1 characterized in that it comprises a filiform body 6 having a plurality of contiguous segments, the filiform body 6 having a peripheral surface 5 which defines at least one outer circular arc x the along the filiform body 6 and at least one inner circular arc y along the filiform body 6, the filiform body 6 comprising at least one attachment means 2 of an active formulation and / or a device for analyzing or measuring and / or a device for controlling the release of active principle (s), said fixing means 2 being disposed on the peripheral surface 5 of said filamentary body 6 along said inner circle arc y, and allowing direct contact between said formulation and / or said device (s) and the capsular medium.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises a fixing means 2.  [000172] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises two or more fastening means 2.  [000173] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises three fixing means 2.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises four fixing means 2.  [000175] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises five fixing means 2.  [000176] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises six fixing means 2.  [000177] In one embodiment, the capsular implant 1 according to the invention is characterized in that its shape is circular, open circular, semicircular, pseudo-circular or pseudo-circular open.  [000178] In one embodiment, at least one fastening means 2 is an open and non-closed chamber in and / or on the surface of said filiform body 6 and / or a projection.  In one embodiment, the capsular implant 1 according to the invention is characterized in that its shape is circular open, semicircular or pseudo-circular open.  [000180] In one embodiment, the capsular implant 1 according to the invention is characterized in that its shape is semicircular.  [000181] In one embodiment, at least one fastening means 2 is an open and non-closed chamber chosen from the following forms: chamber 2a of said filiform body 6, chamber 2c at the surface of said filiform body 6, chamber 2b in at least one of the free ends of the implant 1.  [000182] In one embodiment, the non-closed opening 7 of at least one chamber has a spacing taken in its smallest dimension z between 0.01 and 1.5 mm.  In one embodiment, the non-closed opening 7 of at least one chamber has a spacing taken in its smallest dimension z between 0.01 and 1 mm.  [000184] In one embodiment, the non-closed opening 7 is made up of a plurality of openings, for example holes with a diameter of between 0.1 and 0.5 mm, preferably between 0, 2 mm and 0.4 mm.  In one embodiment, the largest dimension of the section 20 of said filamentary body 6 of said implant 1 is between 0.1 and 3 mm.  In one embodiment, the largest dimension of the section of said filamentary body 6 of said implant 1 is between 1 and 2 mm.  In one embodiment, the ratio between the spacing of the opening 7 taken in its smallest dimension z and the largest dimension of the section 25 of said filiform body 6 of said implant 1 is between 0.1. and 0.9.  In one embodiment, at least one fastening means 2 is a protrusion chosen from the following forms: projecting ring 2d on said filiform body 6, second cantilever on said filiform body 6 and projecting housing 2f 30 in said filiform body 6.  In one embodiment, at least one fastening means 2 is an open and non-closed chamber 2b made in one of the two free ends of said capsular implant 1.  [000190] In one embodiment, the capsular implant 1 according to the invention is characterized in that it consists of a material composed of at least one polymer.  [000191] In one embodiment, the capsular implant 1 according to the invention is characterized in that the polymer is chosen from acrylic polymers chosen from the group comprising PMMA (poly (methyl methacrylate)), HPMA (hydroxypropyl methacrylate), MMA (methyl methacrylate), BMA (butyl methacrylate), HMA (hexyl methacrylate), LMA (lauryl methacrylate), HEMA (polyhydroxyethylmethacrylate), PEMA (poly (ethyl methacrylate)) and In one embodiment, the polymer is chosen from acrylic polymers, vinyl polymers, silicone polymers, siloxanes, the other polymers and / or copolymers of these polymers and / or the copolymers of these polymers. or mixtures thereof, the polymers being crosslinkable or uncrosslinked.  [000192] In one embodiment, the polymer is chosen from hydrophilic acrylic polymers.  [000193] In one embodiment, the polymer is selected from hydrophobic acrylic polymers.  [000194] In one embodiment, the capsular implant 1 according to the invention is characterized in that the polymer is chosen from the vinyl polymers chosen from the group comprising the copolymers of polyvinyl alcohol (PVA), vinyl acetate-ethylene (EVA) and / or copolymers of these polymers and / or mixtures thereof, the polymers being cross-linked or non-cross-linked.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the polymer is chosen from silicone polymers, siloxanes and / or copolymers of these polymers and / or mixtures thereof, polymers that can be crosslinked or uncrosslinked.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the polymer is chosen from the other polymers chosen from the group comprising polysulfone capillary fibers, PEEK (polyether ether ketone). PAEK (polyaryl ether ketone), polyetherimide, polyimide, polyesters, polypropylene, polycarbonates, nylons and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or uncrosslinked .  These polymers will be hereinafter called "other polymers".  In one embodiment, the polymer is chosen from acrylic polymers, vinyl polymers, silicone polymers, siloxanes, the other polymers and / or copolymers of these polymers and / or their mixtures, polymers, and the like. may be crosslinked or uncrosslinked.  [000198] In one embodiment, the capsular implant according to the invention is constituted by assembly of structures, each structure having polymers of different types and / or polymers of different molecular mass and / or polymers having different levels. different crosslinking.  [000199] In one embodiment, the capsular implant is formed of several portions of variable composition, such as rigid PMMA segments and more flexible HEMA-MMA copolymer segments.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises (n) means (s) of attachment 2, (m) formulation (s) active (s) and (p) Analysis and control device (s) such as (m) + (p) 5 (n).  [000201] In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is between 3 and 6, (m) is between 1 and 4, (p) is between 0 and 2.  [000202] In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is between 3 and 6, (m) is between 1 and 20 4, (p) is between 1 and 2.  [000203] In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is equal to 3, (m) is equal to 1, (p) is between 0 and 2.  [000204] In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is equal to 4, (m) is equal to 2, (p) is between 0 and 2 [ In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is equal to 5, (m) is equal to 3, (p) is from 0 to 2 [000206] In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is equal to 6, (m) is equal to 4, (p) is between 0 and 2.  [000207] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises at least one active formulation.  [000208] In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active principle chosen from the groups of antibiotics, anti-inflammatories, anti-glaucoma agents, anti-cancer drugs, active principles used in the treatment of AMD, immunosuppressants, antivirals, antifungals, antiallergics, anesthetics and / or any other active agent that can be used to treat a pathology liceil (retinopathies, uveitis, various infections of the eye).  [000209] In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of antibiotics.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of steroidal or nonsteroidal anti-inflammatory drugs.  [000211] In one embodiment, the anti-inflammatory is cefuroxime.  [000212] In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of anti-glaucomatous agents.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of anticancer agents.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of active ingredients used in the treatment of the AMD.  [000215] In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of immunosuppressants.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of antivirals.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the antifungal groups.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of antiallergics.  [000219] In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of anesthetics.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of any other active ingredient that can be used to treat a pathology of the eye (retinopathies, uveitis, various infections of the eye).  In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of antibiotics and / or anti-inflammatories. .  [000222] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises at least two active formulations, said active formulations comprising respectively at least one active ingredient chosen from the group of antibiotics and at least one active ingredient selected from the group of anti-inflammatories.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it further comprises at least a third active formulation comprising at least one active ingredient chosen from the group of anticancer agents.  In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in solid, liquid, pasty or gel form.  [000225] In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in solid form.  [000226] In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in liquid form.  In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in pasty form.  In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in gel form.  In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in a biodegradable or non-biodegradable solid form.  In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in biodegradable solid form.  [000231] In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in a non-biodegradable solid form.  In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer selected from the group consisting of PLA. (polylactic acid), PLLA (L-polylactic acid), PGA (polyglycolic acid), PLGA (polylactic-co-glycolic acid), PEG (polyethylene glycol), PCL (polycaprolactone), PGLC (poly (glycolide-co-lactide-co-caprolactone) polyanhydrides, PVA (polyvinyl alcohol), EVA (vinyl ethylene acetate), silicone-carbide, polysulfone, POE (poly (orthoesters)), polysaccharides ( hyaluronic acid, chitosan, chondroitin, maltodextrin, amylose, keratan, dextran, heparin, polyalditol, pentosan, starch, etc. ), polyanhydrides, polyamines, polyuretanes, polyesteramides, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, poly (malic acid), polyvinylpyrrolidones, polyamino acids, poly-tyrosine polymers, poloxamer and / or copolymers of these polymers and / or mixtures thereof, the polymers being cross-linked or non-cross-linked.  In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer chosen from the group of polylactic / polyglycolic polymers. comprising PLA (polylactic acid), PLLA (L-polylactic acid), PGA (polyglycolic acid), PLGA (polylactic-glycolic acid), PGLC (poly (glycolide-co-lactide-co-caprolactone)) and or the copolymers of these polymers and / or their mixtures, the polymers being able to be crosslinked or non-crosslinked.  [000234] In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer chosen from the group of vinyl polymers comprising the PVA (polyvinyl alcohol), EVA (vinyl ethylene acetate), polyvinylpyrrolidones and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or uncrosslinked.  In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer chosen from the group of polysaccharides comprising the acid. hyaluronic acid, chitosan, chondroitin, maltodextrin, amylose, keratane, dextran, heparin, polyalditol, pentosan, starch and / or copolymers of these polymers and / or mixtures thereof, polymers that can be crosslinked or uncrosslinked.  In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer chosen from the group of other formulation polymers. including PEG (polyethylene glycol), PCL (polycaprolactone), polyanhydrides, silicone-carbide, polysulfone, POE (poly (orthoesters)), polyanhydrides, polyamines, polyurethane, polyesteramides, polydioxanones, polyacetals polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, poly (malic acid), poly (amino acids), poly-tyrosine polymers, poloxamer and / or copolymers of these polymers and / or mixtures thereof the polymers may be crosslinked or uncrosslinked.  These polymers will hereinafter be referred to as "other formulation polymers".  In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer chosen from the group comprising polylactic / polyglycolic polymers. vinyl polymers, polysaccharides, other formulation polymers and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or non-crosslinkable.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises at least one analysis or measurement device and / or a device for controlling the principle release ( s) active (s).  [000239] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises at least one analysis or measurement device.  [000240] In one embodiment, the at least one analysis or measurement device chosen from the group consisting of chips, biochips, antennas, microprocessors, various biological event sensors, markers or factors in the context of pathologies such as AMD, retinal or uveal melanoma, intraocular pressure sensors, atypical cell presence detector, as well as other devices derived from nanotechnologies.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises at least one device for controlling the release of active principle (s).  [000242] In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises one or at least two transition zones 4.  [000243] In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises a transition zone 4.  [000244] In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises at least two transition zones 4.  In one embodiment, in order to limit cell adhesion and therefore inflammatory reactions, the capsular implant 1 which is the subject of the invention is treated (by impregnation, grafting and / or any other surface treatment) with certain Other compounds, such as, for example, fluorinated derivatives or even polysaccharides In one embodiment, the capsular implant of the invention is treated with heparin or its derivatives.  In one embodiment, the capsular implant of the invention is treated with hyaluronic acid.  [000248] In one embodiment, the capsular implant of the invention is treated with a sulfated polysaccharide.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it is further treated with other compounds selected from the group consisting of: heparin and derivatives, hyaluronic acid, fluorinated derivatives and / or sulfated polysaccharides.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it is further treated with other compounds selected from the group comprising heparin and its derivatives.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it is further treated with hyaluronic acid.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it is further treated with other compounds chosen from the group comprising fluorinated derivatives.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it is further treated with other compounds chosen from the group comprising sulphated polysaccharides.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is round, trigonal, tetragonal, pentagonal, hexagonal, heptagonal, octagonal or any other shape. shape having a number of faces greater than 8.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of round or tetragonal shape.  [000256] In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is round, square or rectangular.  In one embodiment, the capsular implant 1 according to the invention 5 is characterized in that the section of said filiform body 6 is round in shape.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of trigonal shape.  In one embodiment, the capsular implant 1 according to the invention 10 is characterized in that the section of said filiform body 6 is of tetragonal shape.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is square in shape.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of rectangular shape.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of pentagonal shape.  [000263] In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of hexagonal shape.  [000264] In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of heptagonal shape.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of octagonal shape.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of shape having a number of faces greater than 8.  In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises one or at least two gripping zones 3.  [000268] In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises a gripping zone 3.  [000269] In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises at least two gripping zones 3.  [000270] In one embodiment, the capsular implant 1 according to the invention 5 is characterized in that the filiform body 6 comprises two gripping zones 3.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises an armature or core 8 made of a material 10 having greater rigidity than the rest of the material (s) (x) of the implant 1.  In one embodiment, said armature or core 8 is made of at least PMMA (poly (methyl methacrylate)).  In one embodiment, the capsular implant 1 according to the invention is characterized in that at least two fastening means 2 are open and non-closed chambers 2a in the filiform body 6 of the implant 1. , said chambers 2a being separated by a partition 9.  In one embodiment, said partition comprises at least one of the constituent material (s) of the capsular implant 1.  [000275] In one embodiment, said partition comprises at least one material different from the constituent material (s) of the capsular implant 1.  In one embodiment, the capsular implant 1 according to the invention is characterized in that said implant is impregnated with one or more active principle (s).  [000277] In one embodiment, the capsular implant 1 according to the invention is used as part of a post-operative management of a lens surgery.  [000278] In one embodiment, the capsular implant 1 according to the invention is used in the context of post-operative management of a lens surgery in humans.  In one embodiment, the capsular implant 1 according to the invention is used as part of a post-operative management of a lens surgery in animals.  In one embodiment, the capsular implant 1 according to the invention is used in the context of post-operative management of cataractous lens surgery.  [000281] In one embodiment, the capsular implant 1 according to the invention is used in the context of post-operative management of a clear lens surgery.  In one embodiment, the capsular implant 1 according to the invention 5 is used in experimental ophthalmology.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it is used as part of a treatment for human cataract.  In one embodiment, the capsular implant 1 according to the invention is characterized in that it is used in the context of animal cataract treatment.  [000285] In one embodiment, the capsular implant 1 according to the invention is characterized in that it is used in experimental ophthalmology.

Claims (17)

REVENDICATIONS1. Capsular implant (1), characterized in that it comprises a filiform body (6) comprising a plurality of contiguous segments, the filiform body (6) having a peripheral surface (5) which defines at least one outer circular arc (x ) along the filiform body (6) and at least one inner arc (y) along the filiform body (6), the filiform body (6) comprising at least one attachment means (2) of an active formulation and / or an analyzer or measuring device and / or a device for controlling the release of active principle (s), said fixing means (2) being arranged on the peripheral surface (5). ) of said filiform body (6) along said inner circle arc (y) and allowing direct contact between said formulation and / or said device (s) and the capsular medium. 2. Capsular implant (1) according to any one of the preceding claims, characterized in that at least one fastening means (2) is an open and non-closed chamber in and / or on the surface of said filiform body ( 6) and / or a projection. 3. capsular implant (1) according to any one of the preceding claims, characterized in that its shape is semicircular. 25 4. capsular implant (1) according to any one of the preceding claims, characterized in that at least one fastening means (2) is an open and non-closed chamber selected from the following forms: chamber (2a) of said body filiform (6), chamber (2c) on the surface of said filiform body (6), chamber (2b) in at least one of the free ends of the implant (1). 5. Capsular implant (1) according to any one of the preceding claims, characterized in that at least one fastening means (2) is a projection selected from the following forms: projecting ring (2d) on said filiform body ( 6), cantilever (2e) on said filiform body (6) and projecting housing (2f) in said filamentary body (6) of the capsular implant (1). 6. Capsular implant (1) according to any one of the preceding claims, characterized in that at least one fastening means (2) is a chamber (2b) open and non-closed, made in one of the two ends free of said capsular implant (1). 7. capsular implant (1) according to any one of the preceding claims, characterized in that it consists of a material consisting of at least one polymer. 8. Capsular implant (1) according to claim 7, characterized in that the polymer is chosen from acrylic polymers, vinyl polymers, silicone polymers, siloxanes, the other polymers and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or uncrosslinked. The capsular implant (1) according to claim 7, characterized in that the polymer is selected from acrylic polymers selected from the group consisting of PMMA (poly (methyl methacrylate)), HPMA (hydroxypropyl methacrylate), MMA ( methyl methacrylate), BMA (butyl methacrylate), HMA (hexyl methacrylate), LMA (lauryl methacrylate), HEMA (polyhydroxyethylmethacrylate), PEMA (poly (ethyl methacrylate)) and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or uncrosslinked. 10. Capsular implant (1) according to claim 7, characterized in that the polymer is chosen from vinyl polymers chosen from the group comprising copolymers of polyvinyl alcohol (PVA), vinyl acetate-ethylene (EVA) and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or non-crosslinkable. 11. Capsular implant (1) according to claim 7, characterized in that the polymer is selected from silicone polymers, siloxanes and / or copolymers of these polymers and / or mixtures thereof, the polymers may be crosslinked or non-crosslinked. 12. Capsular implant (1) according to claim 7, characterized in that the polymer is selected from polymers selected from the group consisting of polysulfone hair fibers, PEEK (polyether ether ketone), PAEK (poly aryl ether ketone) polyetherimide, polyamide, polyesters, polypropylene, polycarbonates, nylons and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or uncrosslinked. 13. Capsular implant (1) according to any one of the preceding claims, characterized in that it comprises at least one active formulation. 14. Capsular implant (1) according to claim 13, characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of antibiotics, anti-inflammatories, anti-glaucomatous agents, anti-inflammatory agents and anti-inflammatory agents. cancerous, active principles used in the treatment of AMD, immunosuppressants, antivirals, antifungals, antiallergics, anesthetics and / or any other active agent that may be used to treat a pathology of the eye (retinopathies, uveitis, various infections of the eye). 15 15. Capsular implant (1) according to claim 14, characterized in that at least one active formulation comprises, besides the active ingredient, at least one polymer selected from the group consisting of PLA (polylactic acid), PLLA (acid L-polylactic), PGA (polyglycolic acid), PLGA (polylactic-co-glycolic acid), PEG (polyethylene glycol), PCL (polycaprolactone), PGLC (poly (glycolide-co-lactide-co) caprolactone)) polyanhydrides, PVA (polyvinyl alcohol), EVA (vinyl ethylene acetate), silicone-carbide, polysulfone, POE (poly (orthoesters)), polysaccharides (hyaluronic acid, chitosan, chondroitin, maltodextrin, Amylose, keratan, dextran, heparin, polyalditol, pentosan, starch, etc.), polyanhydrides, polyamines, polyurethanes, polyesteramides, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates , poly (malic acid), polyvinylpyrrolidones, poly (amino acids), poly-tyrosine polymers, poloxamer and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or non-crosslinkable. 16. Capsular implant (1) according to any one of the preceding claims, characterized in that it comprises at least one analysis or measurement device. 3028410 48 17. Capsular implant (1) according to any one of the preceding claims, characterized in that it comprises at least one device for controlling the release of active principle (s).